Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00081731 · ClinicalTrials.gov registry record · Phase 3
Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions
A Phase 3 study, sponsored by Baim Institute for Clinical Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 947
- Enrollment target
NCT00081731 is a Phase 3 study that has completed, run by Baim Institute for Clinical Research. The registered enrollment target is 947 participants.
The verdict
NCT00081731, a Phase 3 study, has completed, sponsored by Baim Institute for Clinical Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 947 participants
- Enrollment target
Study Summary
This study will compare medical therapy plus stenting of hemodynamically significant renal artery stenoses versus medical therapy alone in patients with systolic hypertension and renal artery stenosis.
Interventions
- DRUG Atacand/HCT, Caduet
- PROCEDURE GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 947 participants |
| Start Date | 2004-04 |
| Est. Completion | 2013-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00081731
The ClinicalTrials.gov registry entry for NCT00081731 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 947 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baim Institute for Clinical Research, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atacand/HCT, Caduet is the first listed.
NCT00081731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00081731 about?
NCT00081731 is a clinical study titled "Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions". This study will compare medical therapy plus stenting of hemodynamically significant renal artery stenoses versus medical therapy alone in patients with systolic hypertension and renal artery stenosis.
What is the current status of trial NCT00081731?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 947 participants. The study started on 2004-04. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00081731?
The interventions under investigation include: Atacand/HCT, Caduet (DRUG), GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting) (PROCEDURE).
Who is sponsoring clinical trial NCT00081731?
This trial is sponsored by Baim Institute for Clinical Research, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.